. Author manuscript; available in PMC: 2016 Aug 1.

Published in final edited form as: J Pharmacokinet Pharmacodyn. 2015 May 31;42(4):375–389. doi: 10.1007/s10928-015-9419-z

Table 2.

Calibration to in vivo dose-ranging and dose-response measurements obtained from Jayaram et al. [12]: prior distributions and posterior distribution summaries.

Parameter^a (units)

Prior

Posterior^b

PBPK model parameters

F _a

U(0.48, 1.0)^c

0.59(0.07)

k_a (1/d)

U(18.0, 59)

36(10)

CL_C (L/d/kg^0.75)

U(0.46, 1.5)

0.58(0.06)

P_M

U(0.10, 1.4)

1.1(0.2)

Drug-bacteria parameters

f_LU

U(0.14, 0.46)

0.28(0.08)

k_{\max}^{E x} (1 / d)

U(1.8, 26)

17(6)

{E C}_{50}^{E x} (mg / L)

U(0.17, 2.3)

1.0(0.6)

γ^Ex

U(0.09, 1.3)

0.62(0.3)

k_{\max}^{I n} (1 / d)

U(0.16, 2.3)

2.0(0.2)

{E C}_{50}^{I n} (mg / L)

U(0.45, 6.3)

4.5(1)

γ^In

U(0.06, 0.9)

0.72(0.10)

TB model parameters

α_I (1/d)

U(0.24, 0.76)

0.58(0.1)

k₁ (1/d)

U(0.05, 0.75)

0.55(0.1)

c₁ (cell/mL)

U(1.3 ×10⁵,1.9 ×10⁶)

5.0 ×10⁵(3 ×10⁵)

U(12, 38)

29(5)

U(a,b); Uniform distribution over [a, b].

Parameter definitions are given in Table 1.

Mean(SD).

Truncated to exclude values greater than 1.